DNA-dependent RNA polymerase II (RNAP II) largest subunit RPB1 C-terminal domain (CTD) kinases, including CDK9, are serine/threonine kinases known to regulate transcriptional initiation and elongation by phosphorylating Ser 2, 5, and 7 residues on CTD. Given the reported dysregulation of these kinases in some cancers, we asked whether inhibiting CDK9 may induce stress response and preferentially kill tumor cells. Herein, we describe a potent CDK9 inhibitor, LY2857785, that significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines. This molecule inhibits the growth of a broad panel of cancer cell lines, and is particularly efficacious in leukemia cells, including orthotopic leukemia preclinical models as well as in ex vivo acute myeloid leukemia and chronic lymphocytic leukemia patient tumor samples. Thus, inhibition of CDK9 may represent an interesting approach as a cancer therapeutic target, especially in hematologic malignancies.

Epidermal growth factor receptor (EGFR) is often overexpressed in a variety of human cancers, and its expression is associated with poor prognosis for many cancer types. However, an accurate technique to noninvasively image EGFR expression in vivo is not available in the clinical setting. In this research, an Affibody analog, anti-EGFR Ac-Cys-ZEGFR:1907, was successfully site-specifically 18F-labeled for PET of EGFR expression. Methods The prosthetic group N-[2-(4-18F-fluorobenzamido) ethyl] maleimide (18F-FBEM) was conjugated to Ac-Cys-ZEGFR:1907 under mild conditions (pH 7) to produce the probe 18F-FBEM-Cys-ZEGFR:1907. The binding affinity and specificity tests of 18F-FBEM-Cys-ZEGFR:1907 to EGFR were conducted using A431 cancer cells. Small-animal PET and biodistribution studies were conducted on various mice tumor xenograft models with EGFR overexpression (6 types) after injection of approximately 2.0 MBq of 18F-FBEM-Cys-ZEGFR:1907 with or without coinjection of unlabeled Ac-Cys-ZEGFR:1907 for up to 3 h after injection. A correlation study between 18F-FBEM-Cys-ZEGFR:1907 small- animal PET quantification and ex vivo Western blot analysis of tumor EGFR expression was conducted in those 6 types of tumor models. Results 18F-FBEM-Cys-ZEGFR:1907 binds to EGFR with low nanomolar affinity (37 nM) in A431 cells. 18F-FBEM-Cys-ZEGFR:1907 rapidly accumulated in the tumor and cleared from most of the normal organs except the liver and kidneys at 3 h after injection, allowing excellent tumor–to–normal tissue contrast to be obtained. In the A431 tumor xenograft model, coinjection of the PET probe with 45 μg of Ac-Cys-ZEGFR:1907 was able to improve the tumor uptake (3.9 vs. 8.1 percentage of the injected radioactive dose per gram of tissue, at 3 h after injection) and tumor imaging contrast, whereas coinjection with 500 μg of Ac-Cys-ZEGFR:1907 successfully blocked the tumor uptake significantly (8.1 vs. 1.0 percentage of the injected radioactive dose per gram of tissue, at 3 h after injection, 88% inhibition, P < 0.05). Moderate correlation was found between the tumor tracer uptake at 3 h after injection quantified by PET and EGFR expression levels measured by Western blot assay (P = 0.007, R = 0.59). Conclusion 18F-FBEM-Cys-ZEGFR:1907 is a novel protein scaffold–based PET probe for imaging EGFR overexpression of tumors, and its ability to differentiate tumors with high and low EGFR expression in vivo holds promise for future clinical translation.

Malondialdehyde (MDA) is a significant biomarker of oxidative stress. Variations of MDA level in biological systems often represent pathological changes that are related with many types of diseases. Although a variety of techniques have been developed for MDA detection, the probing of this biomarker in living cells remains unexplored. Herein, we report a turn-on fluorescent probe, MDAP-1, with a synergistic photoinduced electron transfer (PET)-hydrogen bonding mechanism, which for the first time realizes MDA sensing under physiological conditions with excellent sensitivity and specificity. The probe responds to MDA with a fluorescence enhancement factor (FEF) of up to >170-fold and a large Stokes shift (∼180 nm). Further biological evaluations show that MDAP-1 is able to detect both endogenous and exogenous MDA in living cells. It can be used to track the generation of MDA under oxidative stress, as stimulated by H2O2. We believe the results of this work will be helpful to the studies of MDA-related biological events and the elucidation of the underlying pathological mechanism in the future.

Nuclear medicine with radioisotopes is extremely useful for clinical cancer diagnosis, prognosis, and treatment. Herein, polyethylene glycol (PEG)-modified nanoscale coordination polymers (NCPs) composed of hafnium (Hf) and tetrakis (4-carboxyphenyl) porphyrin (TCPP) are prepared via a one-pot reaction. By chelation with the porphyrin structure of TCPP, such Hf-TCPP-PEG NCPs could be easily labeled with Tc, an imaging radioisotope widely used for single-photon emission computed tomography (SPECT) in a clinical environment. Interestingly, Hf, as a high- Z element in such Tc-Hf-TCPP-PEG NCPs, could endow nontherapeuticTc with the therapeutic function of killing cancer cells, likely owing to the interaction of Hf with γ rays emitted from Tc to produce charged particles for radiosensitization. With efficient tumor retention, as revealed by SPECT imaging, ourTc-Hf-TCPP-PEG NCPs offer exceptional therapeutic results in eliminating tumors with moderate doses of Tc after either local or systemic administration. Importantly, those biodegradable NCPs could be rapidly excreted without much long-term body retention. Our work, showing the success of applying NCPs for radioisotope therapy (RIT), presents a potential concept for the realization of highly effective cancer treatment withTc, a short-half-life (6.0 h) diagnostic radioisotope, which is promising for cancer RIT with enhanced efficacy and reduced side effects.